Goldman Sachs' Buy rating and $133 price target announcement for Xylem is likely to have a positive short-term impact on the stock price. The reinstatement of the Buy rating by a reputable analyst indicates confidence in the company's growth potential, which may attract more investors and drive the stock price up.